BMS gets FDA nod for ozanimod, but launch will be delayedBristol-Myers Squibb’s multiple sclerosis therapy ozanimod has been approved by the FDA right on schedule, but the company Share XBMS gets FDA nod for ozanimod, but launch will be delayedhttps://pharmaphorum.com/news/bms-gets-fda-nod-for-ozanimod-but-launch-will-be-delayed/
Macrophage Pharma goes for gold with new funding roundRichard Staines spoke with Soren Bregenholt, the new CEO of Macrophage Pharma, about the company’s strategy encompassing both Share XMacrophage Pharma goes for gold with new funding roundhttps://pharmaphorum.com/r-d/views-analysis-r-d/macrophage-pharma-goes-for-gold-with-new-funding-round/
Janssen files MS pill, ahead of FDA decision on BMS’ rivalJanssen has filed its ponesimod pill with the FDA for treatment of adults with relapsing multiple sclerosis, days Share XJanssen files MS pill, ahead of FDA decision on BMS’ rivalhttps://pharmaphorum.com/news/janssen-files-ms-pill-ahead-of-fda-decision-on-bms-rival/
France’s MedDay says drug for MS falls at phase 3 hurdleMedDay Pharma has been unable to replicate promising results with its multiple sclerosis therapy MD1003 in a confirmatory Share XFrance’s MedDay says drug for MS falls at phase 3 hurdlehttps://pharmaphorum.com/news/frances-medday-says-drug-for-ms-falls-at-phase-3-hurdle/
AZ picks up $350m after selling hypertension drugsAstraZeneca has picked up a $350m windfall after selling off five hypertension medicines to generics specialist Atnahs Pharma. Share XAZ picks up $350m after selling hypertension drugshttps://pharmaphorum.com/news/az-picks-up-350m-after-selling-hypertension-drugs/
US, EU reviews start for Novartis’ Ocrevus rival ofatumumabNovartis’ cancer therapy ofatumumab has moved closer to its second life as a treatment for multiple sclerosis, with Share XUS, EU reviews start for Novartis’ Ocrevus rival ofatumumabhttps://pharmaphorum.com/news/us-eu-reviews-start-for-novartis-ocrevus-rival-ofatumumab/
Changing how we talk about clinical trialsMultiple sclerosis (MS) patient Elizabeth Kinder tells us why she participated in a clinical trial and why the Share XChanging how we talk about clinical trialshttps://pharmaphorum.com/views-analysis-patients/changing-talk-clinical-trials-ms/
Biogen gears up for Alzheimer’s drug launchThere are serious doubts about whether the FDA will approve Biogen’s Alzheimer’s candidate aducanumab – but is gearing Share XBiogen gears up for Alzheimer’s drug launchhttps://pharmaphorum.com/news/biogen-gears-alzheimers/
Novartis’ Mayzent EU approval offers SPMS patients new optionNovartis’ Mayzent has been approved in Europe for adults with secondary progressive multiple sclerosis (SPMS) and active disease. Share XNovartis’ Mayzent EU approval offers SPMS patients new optionhttps://pharmaphorum.com/news/novartis-mayzent-eu-approval-offers-spms-patients-new-option/
